Table 2 |
||||
|
Identification of the increased neutrophil proteins by the treatment of granulocyte-macrophage colony-stimulating factor (GM-CSF) |
||||
| m/z |
Protein |
Ratio (treated/untreated) |
Fraction |
Accession no. (Swiss-Prot) |
|
|
||||
| 2,176.0 |
S100 calcium binding protein A9 |
5.0 |
Cytosol |
[Swiss-Prot:P06702] |
| 763.4 |
Neuropeptide S |
3.1 |
Cytosol |
[Swiss-Prot:P0C0P6] |
| 963.5 |
S100 calcium binding protein A8 |
2.9 |
Cytosol |
[Swiss-Prot:P05109] |
| 854.4 |
NADH dehydrogenase 1 α subcomplex subunit 3 |
2.7 |
Cytosol |
[Swiss-Prot:O95167] |
| 795.5 |
Membrane-associated guanylate kinase |
2.7 |
Cytosol |
[Swiss-Prot:Q96QZ7] |
| 1,515.7 |
Actin, β |
2.6 |
Cytosol |
[Swiss-Prot:P60709] |
| 825.2 |
Ubiquitin-conjugating enzyme E2 E1 |
7.8 |
Organelle/membrane |
[Swiss-Prot:P51965] |
| 1,791.0 |
Neutrophil gelatinase-associated lipocalin (NGAL) |
4.0 |
Organelle/membrane |
[Swiss-Prot:P80188] |
| 841.2 |
BMP-binding endothelial regulator protein |
3.7 |
Organelle/membrane |
[Swiss-Prot:Q8N8U9] |
| 845.2 |
Glycoprotein M6-b |
3.0 |
Organelle/membrane |
[Swiss-Prot:Q13491] |
| 1,480.0 |
FYVE, RhoGEF and PH domain-containing protein 4 |
2.5 |
Organelle/membrane |
[Swiss-Prot:Q96M96] |
|
|
||||
|
BMP, bone morphogenetic protein; FYVE, phenylalanine (F)/tyrosine (Y)/valine (V)/glutamic acid (E) domain; Rho, Ras homolog; GEF, guanine nucleotide exchange factor; PH, pleckstrin homology. |
||||
|
Katano et al. Arthritis Research & Therapy 2009 11:R3 doi:10.1186/ar2587 |
||||
